Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody[1][2] developed to treat a variety of solid cancer types. In June 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy".[3]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AK104; AK-104 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
